CDK1 and triple-negative breast carcinoma: The utility of proteomics was not just singled out to this check-point inhibitor, Proteolysis targeting chimera D6 in triple-negative breast cancer along a CDC25-CDK1 axis was found by comparing triple-negative breast cancer cell line response against D6 (Wu Y. et al., 2024).